Eastgate Biotech Corp.
ETBI · OTC
12/31/2019 | 12/31/2018 | 12/31/2017 | 12/31/2016 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -26.7% | -13.5% | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | -$0 | -$0 | -$0 | $0 |
| % Margin | -110.4% | -50.6% | -1.9% | – |
| R&D Expenses | $0 | $0 | $0 | $1 |
| G&A Expenses | $0 | $0 | $0 | $2 |
| SG&A Expenses | $3 | $1 | $3 | $2 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $3 | $1 | $3 | $3 |
| Operating Income | -$3 | -$1 | -$3 | -$3 |
| % Margin | -3,282.4% | -989.1% | -2,180.3% | – |
| Other Income/Exp. Net | -$0 | -$0 | -$0 | -$0 |
| Pre-Tax Income | -$4 | -$1 | -$4 | -$3 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$4 | -$1 | -$4 | -$3 |
| % Margin | -3,553.7% | -1,100.3% | -2,363.4% | – |
| EPS | -0.002 | -0.001 | 0 | -0.01 |
| % Growth | -58.3% | – | 100% | – |
| EPS Diluted | -0.002 | -0.001 | 0 | -0.01 |
| Weighted Avg Shares Out | 1,905 | 1,274 | 0 | 305 |
| Weighted Avg Shares Out Dil | 1,905 | 1,274 | 0 | 305 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$3 | -$1 | -$3 | -$3 |
| % Margin | -3,107.2% | -907.2% | -2,115% | – |